Wegovy Authorized as Canada’s First Liver Disease Drug

For years, Canadians living with a serious liver condition known as MASH have been waiting for a breakthrough. Around ~25 per cent of Canadians suffer from liver disease, with an estimated 5.2 per cent of those progressing to a more serious form called MASH.

Up to now, there were no approved medications to treat MASH directly. Patients were often told to focus on diet and exercise while doctors simply monitored their condition, a period of “watchful waiting” that left many feeling anxious and invisible.

That changed on December 10, 2025.

In a historic milestone for Canadian healthcare, Health Canada officially approved the first-ever medication specifically for the treatment of MASH. The drug, Wegovy (semaglutide), has been authorized for adults with moderate to advanced liver scarring.

What is MASH?

MASH (Metabolic dysfunction-Associated Steatohepatitis) is a serious liver disease where excess fat in the liver causes inflammation and cell damage. You may have previously heard this called NASH; the name was recently updated to better reflect that it is a metabolic health issue.

It is a progressive form of liver disease linked to metabolic issues like obesity, type 2 diabetes, and high cholesterol. MASH is particularly dangerous because it is often “silent,” showing no symptoms until it reaches advanced stages. If left untreated, the resulting scarring, which is known as fibrosis, can lead to severe complications like cirrhosis, liver failure, or liver cancer.

A New Tool for Doctors and Patients

Wegovy is a once-weekly injection that belongs to a class of drugs called GLP-1 receptor agonists. In clinical trials, it demonstrated the ability to improve liver health and slow down the progression of scarring.

Health Canada granted the approval under a Notice of Compliance with Conditions (NOC/c). This special pathway is reserved for serious diseases with a high “unmet medical need,” allowing patients access to the medicine while long-term studies continue to confirm its benefits.

Why This Matters

For the millions of Canadians living with MASH, this news is about more than just a new prescription—it is about recognition.

For a long time, patients felt blamed or left behind because there were no pharmaceutical options. This approval validates that MASH is a serious medical condition that requires real therapeutic options, not just lifestyle advice. It reinforces a critical truth: MASH is a metabolic disease, not just a liver condition.

What Happens Next and Cost

As of December 2025, Canadian patients finally have a tangible treatment to discuss with their healthcare teams. This marks the beginning of a new era in liver care focused on:

• Earlier identification: Catching liver damage before it becomes irreversible.
• Risk stratification: Determining which patients need urgent intervention.
• Expanded options: Giving clinicians the tools they need to support their patients effectively.
• Wegovy is generally not covered by provincial public drug plans for weight management alone; provincial drug plans may evolve to cover it for treatment of MASH. Wegovy costs ~$400 per month. Coverage varies significantly by province and at this time requires specific medical criteria, and special authorization. Speak with your healthcare provider and private insurance company to get a comprehensive overview based on your case.

At The Health Insider we hope the conversation around liver health in Canada has officially changed. For the first time, there is a path forward that offers more than just “watchful waiting.” It offers hope. Subscribe today to stay on top of advances in treatment for liver disease.

~ Read more from The Health Insider ~

• 
  Wegovy Authorized as Canada’s First Liver Disease Drug
  No more “watchful waiting.” Health Canada’s approval of Wegovy gives MASH patients their first tangible medical option to fight liver fibrosis.
• 
  The Affordable Superfood Canadians Overlook
  Packed with protein, fibre and key nutrients, beans are a budget-friendly way to boost health and support local farmers.
• 
  Canada Authorizes First-Ever Oral Treatment for Postpartum Depression
  Canada approves ZURZUVAE, the first oral PPD pill. This breakthrough 14-day oral therapy aims to elevate the standard of maternal mental health care.
• 
  The Host Survival Guide: How to Set Boundaries & Delegate for a Stress-Free Holiday
  Stop stressing! This guide offers actionable mental health strategies for hosts, including expert tips on setting boundaries, delegating tasks, and mastering advanced party prep.
• 
  Optometrist vs. Ophthalmologist: Who to See, When and What Your Province Actually Covers
  Stop guessing! This essential guide clarifies the roles of optometrists, ophthalmologists, and opticians, details provincial coverage for you, and sets your eye exam schedule.
• 
  In-Flight & Holiday Comfort: Essential Gear for Stress-Free Travel
  From travel pillows to compression socks, here are the smartest comfort tools to stay rested and stress-free on flights and holiday visits.

The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.